Drug Trial Radar · NCT05057494
A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Last checked: Nov 19, 2026Latest source record: Nov 13, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Active, not recruiting
Enrollment
607
Actual
Start
Sep 12, 2022
Primary completion
Jul 15, 2027
Study completion Apr 10, 2029
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Sep 27, 2021
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- None
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 130 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
A study of acalabrutinib plus venetoclax (AV) versus venetoclax plus obinutuzumab (VO) in previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL).
Conditions
- Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma
Interventions
AcalabrutinibDrug
Dose formulation: Capsule or Tablet
VenetoclaxDrug
Dose formulation: Tablet
ObinutuzumabDrug
Dose formulation: Injection
Primary outcomes
What the sponsor says the trial is designed to measure.
- Progression-free Survival (PFS)Time frame: Until progressive disease (PD) [assessed Up to 6.6 Years].
Locations
37 sites in 7 countries. Site status is shown where the registry gives one.
Research Site
Tucson, Arizona
Research Site
La Jolla, California
Research Site
Longmont, Colorado
Research Site
Jacksonville, Florida
Research Site
Boston, Massachusetts
Research Site
Rochester, Minnesota
Research Site
St Louis, Missouri
Research Site
Buffalo, New York
Research Site
New Hyde Park, New York
Research Site
New York, New York
Research Site
Rochester, New York
Research Site
Charlotte, North Carolina
Research Site
Cleveland, Ohio
Research Site
Eugene, Oregon
Research Site
Nashville, Tennessee
Research Site
Salt Lake City, Utah
Research Site
Charlottesville, Virginia
Research Site
Seattle, Washington
Research Site
Seattle, Washington
Research Site
Clayton, Australia
Research Site
Nedlands, Australia
Research Site
Waratah, Australia
Research Site
Hradec Králové, Czechia
Research Site
Ostrava - Poruba, Czechia
Research Site
Pilsen, Czechia
Research Site
Montpellier, France
Research Site
Tours, France
Research Site
Budapest, Hungary
Research Site
Debrecen, Hungary
Research Site
Bydgoszcz, Poland
Research Site
Gdansk, Poland
Research Site
Katowice, Poland
Research Site
Krakow, Poland
Research Site
Lódz, Poland
Research Site
Lublin, Poland
Research Site
Barcelona, Spain
Research Site
Palma de Mallorca, Spain
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.